

ASX ANNOUNCEMENT

21 October 2020

Cipla Launches wheezo™ Sales and Marketing Activity to Australian Pharmacies

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, today announces that Cipla Australia Pty Ltd, a subsidiary of Cipla Limited (BSE: 500087, NSE: CIPLA) has commenced direct pharmacy sales and marketing activities for wheezo™ under the Exclusive Sales/Marketing, Distribution & Logistics Agreement signed in July 2020.

Mr Marjan Mikel, CEO and Managing Director of Respiri said “I am delighted Cipla have commenced sales and marketing activity to the pharmacy channel in Australia, which is ahead of schedule. Importantly from Respiri’s perspective, we met our contractual commitments for delivery of 2,000 units of wheezo to support their launch initiatives into the Australian pharmacy channel to be delivered October and the balance in January. Further, inventory to meet additional demand generated by the Cipla sales force in the interim is at hand. For asthma patients, this represents an exciting development in gaining access to our device which has been shown to effectively detect and monitor asthma wheeze and accordingly better inform patients, caregivers and treating clinicians on the management of their condition. Pharmacist support and education will be key in ensuring that the patient is well informed about how wheezo can help bring their physician developed asthma management plans to life, in the real world.”

Ms Debbie Lane, Cipla National Sales Manager, was equally positive after the first day of active sale force promotion to pharmacy stating “as National Sales Manager of the Cipla Team I am excited to be part of the launch of wheezo in the Pharmacy channel, what an incredible opportunity to be part of this e Health asthma management launch, wheezo puts asthma management in the hands of a patient and will give reassurance and peace of mind to parents and caregivers. Wheezo complements Cipla’s Asthma product presence in Retail Pharmacies such as Fluticasone + Salmeterol Cipla Inhaler & Fluticasone Cipla Inhalers, thereby extending Respiratory offerings to Pharmacies and Patients in the Australian community”.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 21 October 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device records wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respi Limited

About Cipla Limited and Cipla

Australia Established in 1935, Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth through deep and wide portfolio and strong patient relationships across our home markets of India, South Africa, US, Australia and other key regulated and emerging markets. Cipla Limited has the one of the world's largest range of inhaled medication and devices for respiratory disease and manufactures more than 100 million inhalers annually. Cipla's respiratory products are exported to more than 100 countries – every minute someone somewhere is using a form of Cipla medication or a delivery system. Cipla Australia, based in Melbourne, has grown to become a leading integrated generics and ethical pharmaceuticals supplier, marketer and distributor in Australia. Cipla Australia has more than 200 products listed with the TGA.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.